Search - tctmd.com

Displaying 1 - 20 of 52

Sort: Relevancy | Date

News Opinion Editor's Corner TCT 2025

What’s Going to Be Hot at TCT 2025

Michael O'Riordan

October 09, 2025

News Conference News VIVA 2024

Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK

L.A. McKeown

November 05, 2024

News Opinion Editor's Corner TCT 2024

What’s Going to Be Big at TCT 2024?

Michael O'Riordan

October 17, 2024

News Daily News

FDA Approves Bioresorbable Scaffold for BTK Lesions

Michael O'Riordan

April 29, 2024

News Daily News

BASIL-3: More Questions Than Answers About Drug-Coated Devices in CLTI

L.A. McKeown

April 24, 2024

News Daily News

DETECT: No Long-term Harm From Paclitaxel Devices in PAD

L.A. McKeown

March 25, 2024

Presentation TCT 2023

TCT 649: Impact of a Novel Hybrid Nano-coated Nitinol Drug-eluting Stent (Hybrid-DES) on Below-the-knee Atherosclerotic Disease: 2023 Update

Presenter: Terumitsu Hasebe

October 25, 2023

News Conference News TCT 2023

Paclitaxel Safety Questions in PAD: Will ‘Capstone’ Data Close the Door?

L.A. McKeown

October 24, 2023

Presentation TCT 2023

TCT 74: Drug-Eluting Stent Versus Drug-Coated Balloon Revascularization in Patients With In-stent Restenosis in Small Coronary Arteries.

Presenter: Wojciech Wanha

October 24, 2023

Presentation TCT 2023

TCT 60: Long-Term Outcomes Following Drug-Coated Balloons Versus Thin-Strut Drug-Eluting Stents for Treatment of In-Stent Restenosis in Chronic Coronary Syndrome (CCS Dragon-Registry)

Presenter: Wojciech Wanha

October 24, 2023

News Opinion Editor's Corner

What’s Going to Be Hot at TCT 2023

Shelley Wood

October 19, 2023

News Daily News

FDA: All Restrictions on Paclitaxel Devices for PAD Are Removed

L.A. McKeown

July 11, 2023

News Conference News LINC 2023

Early Data on Temporary Spur in BTK PAD Show Efficacy, Limited Recoil

L.A. McKeown

June 09, 2023

News Conference News LINC 2023

FDA Approves DETOUR for Percutaneous Bypass in Long, Complex SFA

L.A. McKeown

June 08, 2023

News Daily News

REVIVE Injects Fresh Data Into Surgery vs Stenting Controversy for PAD

L.A. McKeown

January 24, 2023

News Daily News

High Lp(a) May Predict Risk of CV and Limb Events in PAD

L.A. McKeown

July 18, 2022

News Conference News TVT 2022

More Support for Single Antiplatelet Therapy After TAVI

Michael O'Riordan

June 10, 2022

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for March 2022

Caitlin E. Cox

April 01, 2022

News Conference News VIVA 2021

EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions

L.A. McKeown

October 12, 2021

News Conference News VIVA 2021

Diverting or Swirling, New Blood-Flow Tech Shows Promise for CLTI

L.A. McKeown

October 08, 2021

Advertisement

What’s Going to Be Hot at TCT 2025

Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK

What’s Going to Be Big at TCT 2024?

FDA Approves Bioresorbable Scaffold for BTK Lesions

BASIL-3: More Questions Than Answers About Drug-Coated Devices in CLTI

DETECT: No Long-term Harm From Paclitaxel Devices in PAD

TCT 649: Impact of a Novel Hybrid Nano-coated Nitinol Drug-eluting Stent (Hybrid-DES) on Below-the-knee Atherosclerotic Disease: 2023 Update

Paclitaxel Safety Questions in PAD: Will ‘Capstone’ Data Close the Door?

TCT 74: Drug-Eluting Stent Versus Drug-Coated Balloon Revascularization in Patients With In-stent Restenosis in Small Coronary Arteries.

TCT 60: Long-Term Outcomes Following Drug-Coated Balloons Versus Thin-Strut Drug-Eluting Stents for Treatment of In-Stent Restenosis in Chronic Coronary Syndrome (CCS Dragon-Registry)

What’s Going to Be Hot at TCT 2023

FDA: All Restrictions on Paclitaxel Devices for PAD Are Removed

Early Data on Temporary Spur in BTK PAD Show Efficacy, Limited Recoil

FDA Approves DETOUR for Percutaneous Bypass in Long, Complex SFA

REVIVE Injects Fresh Data Into Surgery vs Stenting Controversy for PAD

High Lp(a) May Predict Risk of CV and Limb Events in PAD

More Support for Single Antiplatelet Therapy After TAVI

TCTMD’s Top 10 Most Popular Stories for March 2022

EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions

Diverting or Swirling, New Blood-Flow Tech Shows Promise for CLTI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content